DK2270173T3 - Neisseriale kombinationssammensætninger - Google Patents
Neisseriale kombinationssammensætninger Download PDFInfo
- Publication number
- DK2270173T3 DK2270173T3 DK10179061.6T DK10179061T DK2270173T3 DK 2270173 T3 DK2270173 T3 DK 2270173T3 DK 10179061 T DK10179061 T DK 10179061T DK 2270173 T3 DK2270173 T3 DK 2270173T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- sequence
- nos
- protein
- amino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 16
- 241001212279 Neisseriales Species 0.000 title claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 241000588653 Neisseria Species 0.000 claims description 13
- 235000018102 proteins Nutrition 0.000 description 43
- 241000588650 Neisseria meningitidis Species 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 241000894007 species Species 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 2
- 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 101150095079 menB gene Proteins 0.000 description 2
- 229940124731 meningococcal vaccine Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000040340 Oat mosaic virus Species 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Claims (1)
1. Sammensætning omfattende to eller flere forskellige neisseriale proteiner, hvor de to eller flere forskellige neisseriale proteiner indbefatter et første protein fra en Neisseria bakterie og et andet protein fra en Neisseria bakterie, og hvor: (i) det første protein omfatter en aminosyresekvens valgt blandt (a) SEQ ID NO: 3898; og (b) en sekvens, der har mere end 80% sekvensidentitet med SEQ ID NO: 3898; og det andet protein omfatter en aminosyresekvens valgt blandt (a) én af de lige SEQ ID NO valgt blandt SEQ ID NO: 2182 til 2186; og (b) en sekvens, der har mere end 80% sekvensidentitet med én af de lige SEQ ID NO: 2182 til 2186; eller (ii) det første protein omfatter en aminosyresekvens valgt blandt (a) SEQ ID NO: 3900; og (b) en sekvens, der har mere end 80% sekvensidentitet med SEQ ID NO: 3900; og det andet protein omfatter en aminosyresekvens valgt blandt (a) én af de lige SEQ ID NO valgt blandt SEQ ID NO: 2182 til 2186; og (b) en sekvens, der har mere end 80% sekvensidentitet med én af de lige SEQ ID NO: 2182 til 2186; eller (iii) det første protein omfatter en aminosyresekvens valgt blandt (a) SEQ ID NO: 3902; og (b) en sekvens, der har mere end 80% sekvensidentitet med SEQ ID NO: 3902; og det andet protein omfatter en aminosyresekvens valgt blandt (a) én af de lige SEQ ID NO valgt blandt SEQ ID NO: 2182 til 2186; og (b) en sekvens, der har mere end 80% sekvensidentitet med én af de lige SEQ ID NO: 2182 til 2186.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9911692.3A GB9911692D0 (en) | 1999-05-19 | 1999-05-19 | Antigenic combinations |
| GBGB9919705.5A GB9919705D0 (en) | 1999-08-19 | 1999-08-19 | Antigenic combinations |
| GB0005730A GB0005730D0 (en) | 2000-03-09 | 2000-03-09 | Antigenic combinations |
| EP07075627A EP1860191A3 (en) | 1999-05-19 | 2000-05-19 | Combination neisserial compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2270173T3 true DK2270173T3 (da) | 2016-03-07 |
Family
ID=27255587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10178238.1T DK2270172T3 (da) | 1999-05-19 | 2000-05-19 | Kombinationssammensætninger af Neisseria. |
| DK10179061.6T DK2270173T3 (da) | 1999-05-19 | 2000-05-19 | Neisseriale kombinationssammensætninger |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10178238.1T DK2270172T3 (da) | 1999-05-19 | 2000-05-19 | Kombinationssammensætninger af Neisseria. |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US7862827B2 (da) |
| EP (6) | EP2270173B1 (da) |
| JP (3) | JP5622344B2 (da) |
| CN (2) | CN100338218C (da) |
| AU (3) | AU783894B2 (da) |
| BR (1) | BR0010721A (da) |
| CA (3) | CA2373236C (da) |
| CY (2) | CY1117239T1 (da) |
| DK (2) | DK2270172T3 (da) |
| ES (2) | ES2563677T3 (da) |
| MX (1) | MXPA01011867A (da) |
| NZ (4) | NZ545647A (da) |
| PT (2) | PT2270173E (da) |
| WO (1) | WO2000071725A2 (da) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2266656A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| AU761780B2 (en) | 1998-05-01 | 2003-06-12 | Glaxosmithkline Biologicals Sa | Neisseria meningitidis antigens and compositions |
| US10967045B2 (en) * | 1998-11-02 | 2021-04-06 | Secretary of State for Health and Social Care | Multicomponent meningococcal vaccine |
| GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| EP1228217B1 (en) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
| MXPA01011867A (es) | 1999-05-19 | 2002-05-06 | Chiron Spa | Composiciones neisseriales de combinacion. |
| GB9916529D0 (en) * | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| AU784203B2 (en) | 1999-10-29 | 2006-02-23 | Glaxosmithkline Biologicals S.A. | Neisserial antigenic peptides |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| JP4763210B2 (ja) * | 2000-02-28 | 2011-08-31 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ナイセリアのタンパク質の異種発現 |
| AU2004203417B2 (en) * | 2000-05-08 | 2008-02-14 | Microscience Limited | Virulence genes, proteins, and their use |
| GB0012079D0 (en) * | 2000-05-18 | 2000-07-12 | Microscience Ltd | Virulence gene and protein, and their use |
| GB0020952D0 (en) * | 2000-08-24 | 2000-10-11 | Microscience Ltd | Genes and proteins and their uses |
| ES2388848T3 (es) | 2001-01-23 | 2012-10-19 | Sanofi Pasteur Inc. | Vacuna meningocócica polivalente preparada con un conjugado de polisacárido y proteína |
| WO2002060936A2 (en) * | 2001-01-31 | 2002-08-08 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
| US7261901B2 (en) | 2001-01-31 | 2007-08-28 | University Of Iowa Research Foundation | Vaccine and compositions for the prevention and treatment of neisserial infections |
| GB0108024D0 (en) | 2001-03-30 | 2001-05-23 | Chiron Spa | Bacterial toxins |
| GB0114940D0 (en) * | 2001-06-19 | 2001-08-08 | Chiron Spa | Gene expression during meningococcus adhesion |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| ATE469915T1 (de) | 2001-07-27 | 2010-06-15 | Novartis Vaccines & Diagnostic | Antikörper gegen das meningokokken adhäsin app |
| GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| AU2012202488B2 (en) * | 2001-09-06 | 2014-01-16 | Glaxosmithkline Biologicals S.A. | Hybrid and tandem expression of Neisserial proteins |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| BR0313100A (pt) * | 2002-08-02 | 2005-06-21 | Glaxosmithkline Biolog Sa | Composição imunogênica, composição imunogênica isolada, vacina, método de tratamento ou prevenção de doença bacteriana gram-negativa, uso da vacina, cepa bacteriana gram-negativa geneticamente manipulada, método para preparar a composição imunogênica, método para preparar a vacina, método de preparar uma imunoglobulina para uso na prevenção ou tratamento de infecção neisserial, preparação de imunoglobulina, preparação farmacêutica, e, uso da preparação farmacêutica |
| GB0220197D0 (en) * | 2002-08-30 | 2002-10-09 | Univ Utrecht | Refolding method |
| EP2255826B1 (en) * | 2002-08-02 | 2016-04-13 | GlaxoSmithKline Biologicals S.A. | Neisserial vaccine compositions comprising a combination of antigens |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| PT2353608T (pt) | 2002-10-11 | 2020-03-11 | Novartis Vaccines And Diagnostics S R L | Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas |
| AU2003288660A1 (en) * | 2002-11-15 | 2004-06-15 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| GB0315021D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| US8119385B2 (en) * | 2005-03-04 | 2012-02-21 | Bp Corporation North America Inc. | Nucleic acids and proteins and methods for making and using them |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| RU2008130395A (ru) * | 2005-12-23 | 2010-01-27 | Империал Инновейшенс Лимитед (Gb) | Вакцины и их применение |
| CU23575A1 (es) * | 2006-03-31 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Composición farmacéutica que comprende la proteína nmb0606 |
| CU23572A1 (es) * | 2006-03-31 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Composición farmacéutica que comprende la proteína nmb0938 |
| US8039007B2 (en) * | 2006-06-29 | 2011-10-18 | J. Craig Venter Institute, Inc. | Polypeptides from Neisseria meningitidis |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| EP3263591B1 (en) * | 2008-02-21 | 2019-03-27 | GlaxoSmithKline Biologicals S.A. | Meningococcal fhbp polypeptides |
| GB0810742D0 (en) * | 2008-06-12 | 2008-07-16 | Univ Nottingham | Enzyme |
| EP2334332A4 (en) * | 2008-09-05 | 2013-01-09 | Id Biomedical Corp Quebec | NEW COMPOSITIONS AND NEW ADJUVANTS |
| GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
| IT1394288B1 (it) * | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
| PT2411048T (pt) | 2009-03-24 | 2020-07-14 | Glaxosmithkline Biologicals Sa | Proteína de ligação ao fator h meningocócica com adjuvante |
| CN103002910A (zh) | 2010-03-10 | 2013-03-27 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物 |
| JP2013522177A (ja) * | 2010-03-11 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | グラム陰性細菌性、例えば髄膜炎菌性の感染または疾患に対する免疫原性組成物またはワクチン |
| EP2585106A1 (en) | 2010-06-25 | 2013-05-01 | Novartis AG | Combinations of meningococcal factor h binding proteins |
| MX2013001087A (es) | 2010-07-30 | 2013-06-05 | Univ Griffith | Proteinas de porina por a de neisseria meningitidis recombinantes. |
| MX350142B (es) | 2010-08-23 | 2017-08-28 | Wyeth Llc * | Formulaciones estables de antigenos rlp2086 de neisseria meningitidis. |
| GB201014967D0 (en) * | 2010-09-09 | 2010-10-20 | Univ Southampton | Composition |
| GB201015132D0 (en) * | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
| EP3549601B1 (en) | 2010-09-10 | 2021-02-24 | Wyeth LLC | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| WO2012032498A2 (en) | 2010-09-10 | 2012-03-15 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
| WO2012059593A1 (en) * | 2010-11-05 | 2012-05-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vaccines for preventing meningococcal infections |
| GB201102090D0 (en) * | 2011-02-08 | 2011-03-23 | Univ Sheffield | Antigenic polypeptide |
| GB201120634D0 (en) * | 2011-11-30 | 2012-01-11 | Univ Sheffield | Adjuvant polypeptide |
| AU2013214105A1 (en) * | 2012-02-02 | 2014-07-24 | Novartis Ag | Promoters for increased protein expression in meningococcus |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| MX359256B (es) | 2012-03-09 | 2018-09-19 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| US10376573B2 (en) | 2012-06-14 | 2019-08-13 | Glaxosmithkline Biologicals Sa | Vaccines for serogroup X meningococcus |
| GB201211154D0 (en) * | 2012-06-22 | 2012-08-08 | Univ Southampton | Composition |
| JP2015524418A (ja) | 2012-07-27 | 2015-08-24 | アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのｃｄ１４７ |
| EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
| US9725701B2 (en) | 2013-03-15 | 2017-08-08 | Iowa Corn Promotion Board | Prokarytoic-type isocitrate dehydrogenase and its application for improving nitrogen utilization in transgenic plants |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| EP3229835A1 (en) * | 2014-12-09 | 2017-10-18 | Sanofi Pasteur | Compositions comprising n. meningitidis proteins |
| CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
| PT3506935T (pt) | 2016-09-02 | 2024-04-01 | Sanofi Pasteur Inc | Vacina contra neisseria meningitidis |
| SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| WO2020023717A2 (en) * | 2018-07-25 | 2020-01-30 | The Trustees Of Indiana University | Diagnostic assay for a strain of neisseria meningitidis |
| US11618902B2 (en) * | 2020-03-30 | 2023-04-04 | Jiangnan University | Bacillus subtilis for producing N-acetylneuraminic acid and application thereof |
| CN111394410B (zh) * | 2020-03-30 | 2022-02-01 | 江南大学 | 一种高催化活性神经氨酸合酶及应用 |
| US11579093B2 (en) | 2020-04-22 | 2023-02-14 | SciLogica Corp. | Optical component |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
| US4239749A (en) * | 1979-09-27 | 1980-12-16 | United States Of America | Neisseria gonorrhoeae vaccine |
| EP0273116A3 (en) | 1986-10-09 | 1990-05-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Gonococcal and meningococcal polypeptides, vaccines and diagnostics |
| JPH01125328A (ja) | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
| NL8803111A (nl) * | 1988-12-19 | 1990-07-16 | Nederlanden Staat | Multivalent meningococcen klasse i buitenmembraaneiwit vaccin. |
| EP0467714A1 (en) | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | The class II protein of the outer membrane of neisseria meningitidis |
| ATE174625T1 (de) | 1991-03-14 | 1999-01-15 | Imclone Systems Inc | Rekombinante hybride porinepitope |
| FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
| ATE190502T1 (de) | 1993-05-13 | 2000-04-15 | American Cyanamid Co | Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken |
| US5439808A (en) | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
| ATE173634T1 (de) | 1994-04-20 | 1998-12-15 | Us Army | Impfstoff gegen gram-negative bakterielle infektionen |
| FR2720408B1 (fr) | 1994-05-31 | 1996-08-14 | Pasteur Merieux Serums Vacc | Fragments Tbp2 de Neisseria meningitidis. |
| IL117483A (en) * | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
| ES2217325T5 (es) * | 1995-09-18 | 2009-04-01 | United States Army Medical Research Materiel Command (Usamrmc) | Metodos mejorados para la produccion de vacunas de subunidades multivalentes de proteosomas acomplejados no covalentemente. |
| FR2739624B1 (fr) | 1995-10-10 | 1997-12-05 | Pasteur Merieux Serums Vacc | Nouvelle sous-unite tbp2 de neisseria meningitidis |
| EP0877816A1 (en) | 1996-02-01 | 1998-11-18 | North American Vaccine, Inc. | Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines |
| WO1998017805A2 (en) | 1996-10-24 | 1998-04-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer Office | Invasion associated genes from neisseria meningitidis serogroup b |
| EP0942983B2 (en) | 1996-10-31 | 2014-09-10 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
| NZ502437A (en) | 1997-07-17 | 2001-11-30 | Baxter Healthcare Sa | Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate |
| CN1204253C (zh) * | 1997-08-15 | 2005-06-01 | 乌得勒支大学 | 奈瑟氏球菌乳铁蛋白结合蛋白 |
| CA2308606A1 (en) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
| US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
| EP2278011A3 (en) * | 1998-01-14 | 2012-03-07 | Novartis Vaccines and Diagnostics S.r.l. | Neisseria meningitidis antigens |
| GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| US20070026021A1 (en) | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
| AU761780B2 (en) | 1998-05-01 | 2003-06-12 | Glaxosmithkline Biologicals Sa | Neisseria meningitidis antigens and compositions |
| AT2941U1 (de) | 1998-05-06 | 1999-07-26 | Fleischhacker Gerhard | Flexible flüssigkeitssperre |
| ES2278446T3 (es) | 1998-05-29 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Vacunas combinadas b/c contra la meningitis. |
| EP1741443B1 (en) | 1998-05-29 | 2014-05-21 | Novartis Vaccines and Diagnostics, Inc. | Combination meningitidis B/C vaccines |
| US6248329B1 (en) | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| MXPA01003557A (es) * | 1998-10-09 | 2004-04-05 | Chiron Corp | Secuencias genomicas de neisseria y metodos para su uso. |
| GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| US20030215469A1 (en) | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
| JP4812942B2 (ja) * | 1999-02-26 | 2011-11-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強 |
| EP1228217B1 (en) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
| AU780308B2 (en) | 1999-04-30 | 2005-03-17 | J. Craig Venter Institute, Inc. | Neisseria genomic sequences and methods of their use |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| MXPA01011867A (es) | 1999-05-19 | 2002-05-06 | Chiron Spa | Composiciones neisseriales de combinacion. |
| AU784203B2 (en) | 1999-10-29 | 2006-02-23 | Glaxosmithkline Biologicals S.A. | Neisserial antigenic peptides |
| WO2001034642A2 (en) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Control of neisserial membrane synthesis |
| EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| HUP0300696A3 (en) | 2000-01-25 | 2004-10-28 | Univ Queensland Brisbane | Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha |
| JP4763210B2 (ja) | 2000-02-28 | 2011-08-31 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ナイセリアのタンパク質の異種発現 |
| NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
| EP1322328B1 (en) | 2000-07-27 | 2014-08-20 | Children's Hospital & Research Center at Oakland | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| WO2002083711A2 (en) | 2001-04-17 | 2002-10-24 | Chiron Corporation | Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies |
| RU2323002C2 (ru) | 2001-07-26 | 2008-04-27 | Чирон Срл. | Вакцины, содержащие алюминиевые адъюванты и гистидин |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| ATE469915T1 (de) * | 2001-07-27 | 2010-06-15 | Novartis Vaccines & Diagnostic | Antikörper gegen das meningokokken adhäsin app |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
| EP2255826B1 (en) | 2002-08-02 | 2016-04-13 | GlaxoSmithKline Biologicals S.A. | Neisserial vaccine compositions comprising a combination of antigens |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| PT2353608T (pt) | 2002-10-11 | 2020-03-11 | Novartis Vaccines And Diagnostics S R L | Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas |
| AU2003288660A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| WO2004054611A1 (en) | 2002-12-16 | 2004-07-01 | Nasjonalt Folkehelseinstitutt | Meningococcal vaccine based on outer membrane proteins porb2 and pora |
| CA2512917A1 (en) | 2003-01-15 | 2004-08-05 | Wyeth Holdings Corporation | Methods for increasing neisseria protein expression |
| DK1587537T3 (da) | 2003-01-30 | 2012-07-16 | Novartis Ag | Injicerbare vacciner mod multiple meningococ-serogrupper |
| US20070253964A1 (en) | 2003-04-16 | 2007-11-01 | Zlotnick Gary W | Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease |
| GB0315021D0 (en) | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| SI1961426T1 (sl) | 2003-10-02 | 2011-10-28 | Novartis Ag | Kombinirana cepiva proti meningitisu |
| EP1706481A2 (en) | 2003-12-23 | 2006-10-04 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0409748D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
| GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| RU2432962C2 (ru) | 2005-01-27 | 2011-11-10 | Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд | Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| WO2008001244A2 (en) | 2006-06-23 | 2008-01-03 | Harun Aksoy | A stone |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| WO2008125985A2 (en) | 2007-04-11 | 2008-10-23 | Novartis Ag | Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes |
| JP5637848B2 (ja) | 2007-06-04 | 2014-12-10 | ノバルティス アーゲー | 髄膜炎ワクチンの製剤化 |
| US20090035328A1 (en) | 2007-08-02 | 2009-02-05 | Dan Granoff | fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS |
| EP3263591B1 (en) | 2008-02-21 | 2019-03-27 | GlaxoSmithKline Biologicals S.A. | Meningococcal fhbp polypeptides |
| ES2557282T3 (es) | 2008-03-10 | 2016-01-25 | Children's Hospital & Research Center At Oakland | Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso |
| JP5723768B2 (ja) | 2008-05-30 | 2015-05-27 | ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ | 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用 |
| CA2733943A1 (en) | 2008-09-03 | 2010-03-11 | Children's Hospital & Research Center At Oakland | Peptides presenting an epitope of an a domain of factor h binding protein and methods of use |
| GB0816284D0 (en) | 2008-09-05 | 2008-10-15 | Nat Biolog Standards Board | Vaccine |
| IT1394288B1 (it) | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
| GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
| WO2010109325A2 (en) | 2009-03-24 | 2010-09-30 | Novartis Ag | Combinations including pneumococcal serotype 14 saccharide |
| PT2411048T (pt) | 2009-03-24 | 2020-07-14 | Glaxosmithkline Biologicals Sa | Proteína de ligação ao fator h meningocócica com adjuvante |
| CN103002910A (zh) | 2010-03-10 | 2013-03-27 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物 |
| CA2790167C (en) | 2010-03-30 | 2021-02-09 | Children's Hospital & Research Center Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
| WO2013177397A1 (en) | 2012-05-24 | 2013-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Multivalent meningococcal conjugates and methods for preparing cojugates |
-
2000
- 2000-05-19 MX MXPA01011867A patent/MXPA01011867A/es active IP Right Grant
- 2000-05-19 ES ES10179061.6T patent/ES2563677T3/es not_active Expired - Lifetime
- 2000-05-19 ES ES10178238.1T patent/ES2563650T3/es not_active Expired - Lifetime
- 2000-05-19 CA CA2373236A patent/CA2373236C/en not_active Expired - Fee Related
- 2000-05-19 NZ NZ545647A patent/NZ545647A/en not_active IP Right Cessation
- 2000-05-19 CA CA2838395A patent/CA2838395C/en not_active Expired - Fee Related
- 2000-05-19 EP EP10179061.6A patent/EP2270173B1/en not_active Expired - Lifetime
- 2000-05-19 BR BR0010721-2A patent/BR0010721A/pt not_active IP Right Cessation
- 2000-05-19 AU AU50977/00A patent/AU783894B2/en not_active Ceased
- 2000-05-19 EP EP10179491A patent/EP2270174A1/en not_active Withdrawn
- 2000-05-19 WO PCT/IB2000/000828 patent/WO2000071725A2/en active IP Right Grant
- 2000-05-19 NZ NZ515935A patent/NZ515935A/xx not_active IP Right Cessation
- 2000-05-19 NZ NZ536676A patent/NZ536676A/en not_active IP Right Cessation
- 2000-05-19 DK DK10178238.1T patent/DK2270172T3/da active
- 2000-05-19 EP EP10178238.1A patent/EP2270172B1/en not_active Expired - Lifetime
- 2000-05-19 EP EP07075627A patent/EP1860191A3/en not_active Withdrawn
- 2000-05-19 CA CA2929348A patent/CA2929348A1/en not_active Abandoned
- 2000-05-19 PT PT101790616T patent/PT2270173E/pt unknown
- 2000-05-19 DK DK10179061.6T patent/DK2270173T3/da active
- 2000-05-19 CN CNB008106002A patent/CN100338218C/zh not_active Expired - Fee Related
- 2000-05-19 NZ NZ528254A patent/NZ528254A/en not_active IP Right Cessation
- 2000-05-19 CN CN2011104630251A patent/CN102580072A/zh active Pending
- 2000-05-19 JP JP2000620102A patent/JP5622344B2/ja not_active Expired - Fee Related
- 2000-05-19 EP EP00935438A patent/EP1179072A2/en not_active Ceased
- 2000-05-19 PT PT101782381T patent/PT2270172E/pt unknown
- 2000-05-19 EP EP10179168A patent/EP2258851A1/en not_active Withdrawn
-
2004
- 2004-11-05 US US10/982,703 patent/US7862827B2/en not_active Expired - Fee Related
- 2004-11-09 US US10/984,376 patent/US20050244436A1/en not_active Abandoned
-
2006
- 2006-03-20 AU AU2006201153A patent/AU2006201153B2/en not_active Ceased
-
2007
- 2007-05-24 JP JP2007138403A patent/JP2007224047A/ja active Pending
-
2009
- 2009-02-27 AU AU2009200865A patent/AU2009200865B2/en not_active Ceased
-
2010
- 2010-12-27 US US12/979,239 patent/US20110104193A1/en not_active Abandoned
-
2012
- 2012-02-03 US US13/366,226 patent/US20120135026A1/en not_active Abandoned
- 2012-11-22 JP JP2012256105A patent/JP2013047274A/ja active Pending
-
2013
- 2013-06-18 US US13/921,087 patent/US20140037668A1/en not_active Abandoned
-
2014
- 2014-05-21 US US14/284,326 patent/US20150174231A1/en not_active Abandoned
-
2016
- 2016-02-03 US US15/015,004 patent/US9610342B2/en not_active Expired - Fee Related
- 2016-02-03 US US15/015,041 patent/US9364528B1/en not_active Expired - Fee Related
- 2016-03-01 CY CY20161100175T patent/CY1117239T1/el unknown
- 2016-03-01 CY CY20161100173T patent/CY1117235T1/el unknown
-
2017
- 2017-02-21 US US15/438,584 patent/US20170165346A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2270173T3 (da) | Neisseriale kombinationssammensætninger | |
| JP5564297B2 (ja) | 髄膜炎菌タンパク質ｎｍｂ１８７０の複数の改変体 | |
| RU2475495C2 (ru) | Гибридная и тандемная экспрессия белков нейссерий | |
| US11708394B2 (en) | Modified meningococcal FHBP polypeptides | |
| Panatto et al. | Neisseria meningitidis B vaccines | |
| Masignani et al. | Reverse vaccinology: a genome-based approach for vaccine development | |
| Christodoulides et al. | Novel approaches to Neisseria meningitidis vaccine design | |
| JP2022177111A (ja) | 改変髄膜炎菌ｆＨｂｐポリペプチド | |
| Hadad et al. | Novel meningococcal 4 CM enB vaccine antigens–prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae | |
| Holst | Strategies for development of universal vaccines against meningococcal serogroup B disease | |
| EA038940B1 (ru) | Менингококковые вакцины | |
| Williams et al. | Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens | |
| Matthias et al. | Heterogeneity in non‐epitope loop sequence and outer membrane protein complexes alters antibody binding to the major porin protein PorB in serogroup B Neisseria meningitidis | |
| Hou et al. | ConformationalEpitopes Recognized by Protective Anti-Neisserial Surface Protein AAntibodies | |
| Wheeler et al. | Exploring the proteome of meningococcal outer membrane vesicle vaccines | |
| Sardiñas et al. | Assessment of vaccine potential of the Neisseria-specific protein NMB0938 | |
| Jong et al. | Feasibility and therapeutic strategies of vaccines against Porphyromonas gingivalis | |
| RU2244749C2 (ru) | Композиция для лечения или профилактики инфекции, вызванной бактерией neisseria | |
| AU2016228231A1 (en) | Combination Neisserial compositions | |
| Kaaijk et al. | Routine vaccination against MenB | |
| Suker et al. | Prospects offered by genome studies for combating meningococcal disease by vaccination | |
| Serino et al. | Meningococcal diseases: From genomes to vaccines | |
| Lattanzi et al. | Novel vaccination strategies | |
| Menéndez et al. | Recent advances in the pathogenic neisseria research |